Fig. 1 · Structure

Documents & Downloads

Motesanib Diphosphate (AMG 706 Diphosphate)

Cat. No. A10608 CAS 857876-30-3

VEGFR inhibitor

Motesanib, also known as AMG-706, is an orally administered multikinase inhibitor that selectively targets VEGF receptors, platelet-derived growth factor receptors, and Kit receptors.

In Stock

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Target & Activity

Target Activity Value
VEGFR1 IC50 2nM
VEGFR2 IC50 3nM
VEGFR2/Flk1 IC50 6nM
VEGFR3 IC50 6nM
Kit IC50 8nM
RET IC50 59nM
PDGFR IC50 84nM
FGFR IC50 >2.8μM
EGFR IC50 >3μM
Src IC50 >3μM
p38 IC50 >3μM

11 targets · Scroll to view more

Motesanib Diphosphate (AMG 706 Diphosphate) Research Summary

This section summarizes 1 in vitro study and 3 in vivo studies of Motesanib Diphosphate (AMG 706 Diphosphate) from 3 published references.

Motesanib Diphosphate (AMG 706 Diphosphate) In Vitro Studies

Motesanib was evaluated in stably transfected Ba/F3 cells carrying Δ552-559 after treatment for 24 hours. The cell survival IC50 was 0.4 nM. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Motesanib in stably transfected Ba/F3 cells

Cell-based study · Ba/F3 cells; Δ552-559 [1]

Stably transfected Ba/F3 cells carrying Δ552-559 were treated with Motesanib for 24 hours. The cell survival IC50 was 0.4 nM.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Cell viabilityIC50 0.4 nM[1]

Literature-Reported Treatment Conditions

Treatment concentration
single 10-fold serial dilutions; 0.1 μM
Exposure duration
24 hours
Vehicle
0.2% DMSO
Reported limits
Not stated in the sentences used: route.
Methods and source locations

Compound reported in the paper: Motesanib

The paper names Motesanib without stating the salt or form; not verified as the diphosphate form supplied as A10608. No dose conversion or lot validation.

Methods > Ba/F3 Functional Viability Assay (S40, S41, S42, S43, S45); Table 2 (T2.h1, T2.h2, T2.r3)

Cell viability: Cell viability; comparator: vehicle control (0.2% DMSO) — Methods > Ba/F3 Functional Viability Assay (S42); Table 2 (T2.h1, T2.h2, T2.r3)

Motesanib Diphosphate (AMG 706 Diphosphate) In Vivo Studies

Oral Motesanib significantly inhibited A549 xenograft tumor growth by 45%, 84%, and 107% at twice-daily doses of 7.5 mg/kg, 25 mg/kg, and 75 mg/kg, respectively, compared with vehicle. In male nude mice bearing A375 xenografts, Motesanib administered by intraperitoneal injection markedly impeded tumor growth compared with vehicle control treatment. In Calu-6 xenografts, significant tumor growth inhibition of 66% compared with vehicle was observed only at the highest tested oral dose of 75 mg/kg twice daily for 17 days. [2,3]

Motesanib in A549 tumor xenografts

Animal study · female athymic nude mice; A549 subcutaneous tumor xenografts; 9 to 10 per treatment group [2]

Female athymic nude mice bearing A549 subcutaneous tumor xenografts received oral Motesanib twice daily for 17 days. Tumor growth was significantly inhibited by 45%, 84%, and 107% at 7.5 mg/kg, 25 mg/kg, and 75 mg/kg, respectively, compared with vehicle.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volumetumor growth 45%, 84%, and 107%[2]

Conditions shared by the study groups

Route
orally
Treatment course
BID; for 17 days
Vehicle
water, pH 2.5
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BIDvehiclesignificantly inhibited tumor growth (45%, 84%, and 107%, respectively), compared with vehicle[2]
Motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BID
Model: female athymic nude mice; A549 subcutaneous tumor xenografts; 9 to 10 per treatment group
Methods and source locations

Compound reported in the paper: Motesanib

The paper names Motesanib without stating the salt or form; not verified as the diphosphate form supplied as A10608. No dose conversion or lot validation.

Results > Effect of single-agent motesanib on human NSCLC tumor growth (S8, S11); Methods > Tumor xenograft models (S76, S79, S80); Figure 2 legend (S104, S105)

Tumor volume: Tumor volume; comparator: vehicle — Results > Effect of single-agent motesanib on human NSCLC tumor growth (S11); Figure 2 legend (S104)

Motesanib 7.5 mg/kg BID, 25 mg/kg BID, or 75 mg/kg BID · Results > Effect of single-agent motesanib on human NSCLC tumor growth (S11); Methods > Tumor xenograft models (S80); Figure 2 legend (S105)

Motesanib in A375 tumor xenografts

Animal study · Male nude mice were randomly divided into three groups, A375 cells (1 × 106/point) were injected subcutaneously [3]

Male nude mice bearing subcutaneous A375 xenografts received Motesanib at 7.5 mg/kg by intraperitoneal injection once per day. Treatment markedly impeded xenograft tumor growth compared with the vehicle control treatment group.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
tumor volumesReported result AMG 706 was revealed to markedly impede xenograft tumor growth compared with vehicle control treatment group[3]

Conditions shared by the study groups

Route
intraperitoneal injection
Treatment course
once per day
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Motesanib 7.5 mg/kgvehicle control treatment groupAMG 706 was revealed to markedly impede xenograft tumor growth compared with vehicle control treatment group[3]
Motesanib 7.5 mg/kg
Model: Male nude mice were randomly divided into three groups, A375 cells (1 × 106/point) were injected subcutaneously
Reported limits: Not stated in the sentences used: vehicle.
Methods and source locations

Compound reported in the paper: Motesanib; Compound label in the paper: AMG-706

The paper names Motesanib without stating the salt or form; not verified as the diphosphate form supplied as A10608. No dose conversion or lot validation.

Results > AMG 706 activates MrgprF expression, while inhibits tumor growth (S111, S117, S118, S120); Materials and methods > Animal experiments (S191)

tumor volumes: tumor volumes; comparator: vehicle control treatment group — Results > AMG 706 activates MrgprF expression, while inhibits tumor growth (S111, S120)

Motesanib 7.5 mg/kg · Results > AMG 706 activates MrgprF expression, while inhibits tumor growth (S120); Materials and methods > Animal experiments (S191)

Motesanib in Calu-6 tumor xenografts

Animal study · female CD1 nu/nu mice; Calu-6 subcutaneous tumor xenografts; 9 to 10 per treatment group [2]

Female CD1 nu/nu mice bearing Calu-6 subcutaneous tumor xenografts received oral Motesanib twice daily for 17 days. Significant tumor growth inhibition of 66% compared with vehicle was observed only at the highest tested dose of 75 mg/kg.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Tumor volumetumor growth 66% inhibition[2]

Conditions shared by the study groups

Route
orally
Treatment course
twice daily (BID) for 17 days
Vehicle
water, pH 2.5
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Motesanib 75 mg/kgvehiclea significant inhibitory effect of motesanib on tumor growth (66% inhibition) was only seen at the highest dose tested of 75 mg/kg twice daily (BID) for 17 days compared with vehicle[2]
Motesanib 75 mg/kg
Model: female CD1 nu/nu mice; Calu-6 subcutaneous tumor xenografts; 9 to 10 per treatment group
Methods and source locations

Compound reported in the paper: Motesanib

The paper names Motesanib without stating the salt or form; not verified as the diphosphate form supplied as A10608. No dose conversion or lot validation.

Results > Effect of single-agent motesanib on human NSCLC tumor growth (S8, S12); Methods > Tumor xenograft models (S76, S79, S80); Figure 2 legend (S104)

Tumor volume: Tumor volume; comparator: vehicle — Results > Effect of single-agent motesanib on human NSCLC tumor growth (S12); Figure 2 legend (S104)

Motesanib 75 mg/kg · Results > Effect of single-agent motesanib on human NSCLC tumor growth (S12); Methods > Tumor xenograft models (S80)

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 857876-30-3
Applications VEGFR inhibitor
Formula C22H23N5O.2H3PO4
Molecular Weight 569.4
Synonyms AMG-706; AMG 706 Diphosphate
SMILES
CC1(CNC2=C1C=CC(=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4)C.OP(=O)(O)O.OP(=O)(O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO Warmed: 88 mg/mL (154.54 mM)
Water Warmed: 17 mg/mL (29.85 mM)
Ethanol Insoluble

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
28 mg/mL
Vehicle
Saline

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Motesanib Diphosphate (AMG 706 Diphosphate) Research References

  1. [1] Caenepeel S, Renshaw-Gegg L, Baher A, et al. Motesanib inhibits Kit mutations associated with gastrointestinal stromal tumors. J Exp Clin Cancer Res (2010). PMID: 20633291 DOI: 10.1186/1756-9966-29-96 Source material
  2. [2] Coxon A, Ziegler B, Kaufman S, et al. Antitumor activity of motesanib alone and in combination with cisplatin or docetaxel in multiple human non-small-cell lung cancer xenograft models. Mol Cancer (2012). PMID: 22992329 DOI: 10.1186/1476-4598-11-70 Source material
  3. [3] Shen Q, Han Y, Wu K, et al. MrgprF acts as a tumor suppressor in cutaneous melanoma by restraining PI3K/Akt signaling. Signal Transduct Target Ther (2022). PMID: 35504869 DOI: 10.1038/s41392-022-00945-9 Source material

Added to your cart

View Cart Checkout
Loading...